SCHEMBL10323449

SCHEMBL10323449

O=C(O)c1cc2cnc(N3CCC(O)CC3)nc2[nH]c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 2/20 0.43
▸ DYRK1B Q9Y463 2/20 0.43
▸ HCAR2 Q8TDS4 1/20 0.38
▸ ABL1 P00519 2/20 0.38
▸ EGFR P00533 2/20 0.37
▸ HDAC4 P56524 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ EGLN1 Q9GZT9 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ SMO Q99835 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ PTGER4 P35408 1/20 0.35
▸ CDC7 O00311 1/20 0.34
▸ DBF4 Q9UBU7 1/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ CXCR3 P49682 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10324398 0.89 DYRK1A (0.52) DYRK1ADYRK1BHCAR2HDAC4HDAC1
SCHEMBL10322984 0.86 ALDH1A1 (0.46) DYRK1ADYRK1BHCAR2ALDH1A1LMNA
SCHEMBL10322497 0.84 POLB (0.50) DYRK1ADYRK1BALDH1A1
SCHEMBL10324192 0.84 TNKS (0.43) DYRK1ADYRK1BHCAR2HDAC1HDAC2
SCHEMBL10323015 0.81 DYRK1A (0.53) DYRK1ADYRK1B
SCHEMBL10323016 0.81 DYRK1A (0.53) DYRK1ADYRK1B
SCHEMBL10323683 0.76 MAPK8 (0.46) —
SCHEMBL11951912 0.76 SMN1; SMN2 (0.41) DYRK1ADYRK1BALDH1A1LMNACASP1
SCHEMBL10324214 0.74 POLB (0.45) DYRK1ADYRK1BALDH1A1LMNAOPRK1
SCHEMBL10323700 0.72 ALDH1A1 (0.43) DYRK1ADYRK1BALDH1A1PIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098065-A1 PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO claimed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 — — US claimed
WO-2012098065-A1 PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184542-A1 PYRIDO PYRIMIDINES TYMS, TYMP, DPYD DYRK1A 654/4885DYRK1B 570/4885HCAR2 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback